Live Breaking News & Updates on Current Treatment Landscape

Stay updated with breaking news from Current treatment landscape. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Unmet Needs in Colorectal Cancer Liver Metastases

Ryan Merkow, MD, MS, and Louise Catherine Connell, MB BCh BAO, BMedSc, discuss the current treatment landscape in colorectal cancer liver metastases, highlighting unmet needs in the treatment space. ....

Ryan Merkow , Louise Catherine Connell , Unmet Needs , Colorectal Cancer Liver , Hepatic Artery Infusion , Hepatic Artery Infusion Therapy , Colorectal Cancer , Intrahepatic Cholangiocarcinoma , Current Treatment Landscape , Liver Metastases , Thai Therapy ,

Johnson & Johnson's Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer

/PRNewswire/ Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted TAR-200 Breakthrough Therapy Designation (BTD). ....

United States , United Kingdom , Obrian Kenney , Clin Urol , Kiran Patel , Indianj Urol , Prnewswire Johnson , Exchange Commission , Janssen Biotech Inc , Drug Administration , Janssen Research Development , European Society For Medical Oncology Annual Congress , American Urological Association Annual Meeting Abstract , None Of Janssen Research Development , Clinical Development , Breakthrough Therapy Designation , Novel Targeted Releasing System Based , Ongoing Phase , Therapy Designation , Bacillus Calmette Gu , Vice President , Solid Tumors , Johnson Innovative , Medical Oncology Annual Congress , Urological Association Annual Meeting , Complete Response ,

Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City

- Company speakers include Doug Drysdale, Chief Executive Officer; and Amir Inamdar, MBBS, DNB , MFPM, Chief Medical Officer -

- Featured key opinion leaders include Dr. Maurizio Fava, M.D.,. ....

United Kingdom , United States , New York , Gittem Knudsen , Health Canada , Department Of Psychiatry The Massachusetts , Carlsberg Foundation Researcher Award For Sciences , Program Schedule , Psychiatry Clinical Trials Network , Cybin Inc , Exchange Commission , National Academy Of Medicine , University Of Vienna , Clinical Trials Network , Royal Danish Academy Of Sciences , Panel Discussion , University Of Padova School Medicine , European College Of Neuropsychopharmacology , Drug Administration , Research Program , Neurobiology Research Unit , University Of Copenhagen , Mental Health On , American Society Of Clinical Psychopharmacology , Current Treatment Landscape , Therapeutic Potential ,

Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor -October 23, 2023 at 07:22 am EDT

News Release

Media Contacts:

Suzanne Frost

+1 416-317-0304

Brian Kenney +1 215-620-0111

. ....

United Kingdom , James Wf Catto , Indianj Urol , Clin Urol , Obrian Kenney , Kiran Patel , Jnjinnovmedand Janssen , Exchange Commission , Drug Administration , Clinical Development , Companies Of Johnson , European Society For Medical Oncology , Department Of Oncology , European Society For Medical Oncology Congress , None Of Janssen Research Development , Janssen Research Development , Astex Pharmaceuticals , Us Food Drug Administration , University Of Sheffield , Janssen Biotech Inc , Janssen Pharmaceutical Companies Of Johnson , News Release , Show Improved Rates , Recurrence Free Survival , High Risknon Muscle Invasive Bladder Cancer , Janssen Pharmaceutical Companies ,

First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery system Phase 1 results show a manageable safety profile with limited systemic toxicity, and early complete responses in patients with high-risk and intermediate-risk NMIBC MADRID, Oct. 22, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & […] ....

Comunidad Autonoma De Cataluna , Obrian Kenney , Jeffrey Infante , European Society For Medical Oncology , Companies Of Johnson , Janssen Biotech Inc , Janssen Pharmaceutical Companies Of Johnson , Translational Research , Exchange Commission , Oncology Early Clinical Development , None Of Janssen Research Development , Janssen Research Development , Janssen Pharmaceutical Companies , Late Breaking Mini Oral Presentation Session , European Society , Medical Oncology , Antoni Vilaseca , Global Head , Janssen Research , Bacillus Calmette Gu , Pharmaceutical Companies , Pulmonary Hypertension , Janssen Biotech , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking ,